Quarterly Report III 22/23
September 2022 – May 2023, Diamyd Medical AB (publ), Fiscal year 2022/2023Precision Medicine for Autoimmune Diabetes in Pivotal Phase 3Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com. September 1, 2022 – May 31, 2023 · Net result: MSEK -78.6 (-63.4), third quarter: MSEK -20.6 (-17.1). · Result per share: SEK -1.0 (-0.8), third quarter: SEK -0.3 (-0.2) · Cash flow from operating activities: MSEK -76.4 (-50.7), third quarter: MSEK -24.0 (-35.7) · Cash and short-term